Non-invasive Prenatal Testing (NIPT) Market to Reflect a Modest CAGR Between 2018 and 2026

Non-invasive prenatal
testing is a DNA test on maternal blood to screen pregnancies for the
most common fetal chromosome anomalies such as trisomy 21 that is
Down syndrome, trisomy 18 Edwards syndrome and trisomy 13 Patau
syndrome. Whereas NIPT can also determine the gender of the fetus and
NIPT is highly reliable in over 99% of Down syndrome cases. The
results of the NIPT screening can help doctor to decide the next
steps, including whether to have a diagnostic test like chorionic
villus sampling (CVS) or collected from the amniotic fluid or
placenta, to make sure whether a baby has a chromosome abnormality.
Non-invasive prenatal testing can be performed any time after 9 weeks
into your pregnancy earlier than any other prenatal screening or
diagnostic test.
Download PDF Brochure Of This Report:
https://www.coherentmarketinsights.com/insight/request-pdf/579
Rise in number
of women choosing late pregnancies is expected to fuel the growth of
non-invasive prenatal testing market
The average maternal age nowadays is increased due
to rise in number of working women so the risk of pregnancies has
also increased which shows the growth in the market of NIPT. As a
woman age the risk of having baby with Down syndrome increase but
other factor also play a role, which include the number of existing
siblings and how big is the gap between the child and his immediate
preceding sibling. As according to Centers for Disease Control and
Prevention in year 2016, Down syndrome continues to be the most
common chromosomal disorder, as each year about 6000 babies were born
with Down syndrome in the U.S.
Whereas, Centers for Disease Control and
Prevention also states in 2017 that older mothers are more likely to
have a baby affected by Down syndrome than younger mothers. In other
words, the prevalence of Down syndrome increases as the mother’s
age increases, which is also expected to favor growth of non-invasive
prenatal testing market.
Non-invasive
Prenatal Testing Market Taxonomy:
By Product Type
-
Assay Kits & Reagents
-
Consumables
-
Disposables
-
Next-Generation Sequencing System
-
Instruments
-
PCR Instruments
-
Ultrasound Devices
-
Microarrays
-
Other Instruments
By Method
-
Ultrasound Detection
-
Cell-free DNA in Maternal Plasma Tests
-
Biochemical Screening tests
-
Fetal Cells in Maternal Plasma Tests
By Application
-
Trisomy
-
Micro deletion Syndrome
-
Other Application
By End User
-
Diagnostic Laboratories
-
Hospitals
Market Key Players Include:
GE Healthcare,
Koninklijke Philips N.V., Illumina, Inc., Thermo Fisher Scientific,
Inc., F. Hoffmann-La Roche Ltd., Pacific Biosciences of California,
Inc., PerkinElmer, Inc., QIAGEN N.V., Agilent Technologies, Inc., and
Beijing Genomics Institute.
About Coherent Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market
Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment